Setting

Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Published: 26 Aug 2020 | Report Code: 10247648 | Pages: 96

Asia Pacific influenza treatment market will grow by 6.8% annually with a total addressable market cap of $2,873.1 million over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic. Highlighted with 30 tables and 43 figures, this 96-page report “Asia Pacific Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country. Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs Based on Influenza Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	5
1.1 Industry Definition and Research Scope	5
1.1.1 Industry Definition	5
1.1.2 Research Scope	6
1.2 Research Methodology	9
1.2.1 Overview of Market Research Methodology	9
1.2.2 Market Assumption	10
1.2.3 Secondary Data	10
1.2.4 Primary Data	10
1.2.5 Data Filtration and Model Design	12
1.2.6 Market Size/Share Estimation	13
1.2.7 Research Limitations	14
1.3 Executive Summary	15
2 Market Overview and Dynamics	17
2.1 Market Size and Forecast	17
2.1.1 Impact of COVID-19 on the Market	18
2.2 Major Growth Drivers	20
2.3 Market Restraints and Challenges	24
2.4 Emerging Opportunities and Market Trends	27
2.5 Porter’s Fiver Forces Analysis	31
3 Segmentation of Asia Pacific Market by Product Type	35
3.1 Market Overview by Product Type	35
3.2 Oseltamivir Phosphate	37
3.3 Baloxavir Marboxil	38
3.4 Peramivir	39
3.5 Zanamivir	40
3.6 Other Drugs	41
4 Segmentation of Asia Pacific Market by Influenza Type	42
4.1 Market Overview by Influenza Type	42
4.2 Influenza A	44
4.3 Influenza B	45
4.4 Influenza C	46
5 Segmentation of Asia Pacific Market by Administration Route	47
5.1 Market Overview by Administration Route	47
5.2 Oral Administration	49
5.3 Other Administration Routes	50
6 Segmentation of Asia Pacific Market by Distribution Channel	51
6.1 Market Overview by Distribution Channel	51
6.2 Retail Pharmacy	53
6.3 Hospital Pharmacy	54
6.4 Clinics	55
6.5 Online Stores	56
7 Asia-Pacific Market 2019-2030 by Country	57
7.1 Overview of Asia-Pacific Market	57
7.2 Japan	60
7.3 China	63
7.4 Australia	65
7.5 India	67
7.6 South Korea	69
7.7 Rest of APAC Region	71
8 Competitive Landscape	73
8.1 Overview of Key Vendors	73
8.2 New Product Launch, Partnership, Investment, and M&A	76
8.3 Company Profiles	77
AstraZeneca Plc	77
BioCryst Pharmaceuticals Inc.	79
Biondvax	80
Daiichi Sankyo Company	81
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)	82
GlaxoSmithKline Plc	83
Mylan N.V	84
Natco Pharma Limited	85
Novartis AG	86
Sanofi	87
Seqirus	88
Teva Pharmaceutical Industries Limited	89
9 Investing in Asia Pacific Market: Risk Assessment and Management	90
9.1 Risk Evaluation of Asia Pacific Market	90
9.2 Critical Success Factors (CSFs)	93
Related Reports and Products	96
List Of Tables

Table 1.  Snapshot of Asia Pacific Influenza Treatment Market, 2019-2030	16
Table 2.  Main Product Trends and Market Opportunities in Asia Pacific Influenza Treatment Market	27
Table 3. Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, $ mn	35
Table 4. Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, $ mn	42
Table 5. Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, $ mn	47
Table 6. Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	51
Table 7. APAC Influenza Treatment Market by Country, 2019-2030, $ mn	58
Table 8. Japan Influenza Treatment Market by Product Type, 2019-2030, $ mn	62
Table 9. Japan Influenza Treatment Market by Administration Route, 2019-2030, $ mn	62
Table 10. Japan Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	62
Table 11. China Influenza Treatment Market by Product Type, 2019-2030, $ mn	64
Table 12. China Influenza Treatment Market by Administration Route, 2019-2030, $ mn	64
Table 13. China Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	64
Table 14. Australia Influenza Treatment Market by Product Type, 2019-2030, $ mn	66
Table 15. Australia Influenza Treatment Market by Administration Route, 2019-2030, $ mn	66
Table 16. Australia Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	66
Table 17. India Influenza Treatment Market by Product Type, 2019-2030, $ mn	68
Table 18. India Influenza Treatment Market by Administration Route, 2019-2030, $ mn	68
Table 19. India Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	68
Table 20. South Korea Influenza Treatment Market by Product Type, 2019-2030, $ mn	70
Table 21. South Korea Influenza Treatment Market by Administration Route, 2019-2030, $ mn	70
Table 22. South Korea Influenza Treatment Market by Distribution Channel, 2019-2030, $ mn	70
Table 23. Influenza Treatment Market in Rest of APAC by Country, 2019-2030, $ mn	72
Table 24. AstraZeneca Plc: Company Snapshot	77
Table 25. AstraZeneca Plc: Business Segmentation	77
Table 26. AstraZeneca Plc: Product Portfolio	78
Table 27. AstraZeneca Plc: Revenue, 2016-2018, $ mn	78
Table 28. AstraZeneca Plc: Recent Developments	78
Table 29.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	91
Table 30. Critical Success Factors and Key Takeaways	94
List Of Figures

Figure 1. Research Method Flow Chart	9
Figure 2. Breakdown of Primary Research	11
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	13
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	15
Figure 5. Asia Pacific Influenza Treatment Market, 2019-2030, $ mn	17
Figure 6. Impact of COVID-19 on Business	18
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Influenza Treatment Market	20
Figure 8. GDP per capita in the World, 1960-2018, $ thousand	23
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million	23
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Influenza Treatment Market	24
Figure 11. Investment Opportunity Analysis	28
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Influenza Treatment Market	31
Figure 13. Breakdown of Asia Pacific Influenza Treatment Market by Product Type, 2019-2030, % of Revenue	35
Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%)	36
Figure 15. Asia Pacific Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn	37
Figure 16. Asia Pacific Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn	38
Figure 17. Asia Pacific Influenza Treatment Market: Peramivir, 2019-2030, $ mn	39
Figure 18. Asia Pacific Influenza Treatment Market: Zanamivir, 2019-2030, $ mn	40
Figure 19. Asia Pacific Influenza Treatment Market: Other Drugs, 2019-2030, $ mn	41
Figure 20. Breakdown of Asia Pacific Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue	42
Figure 21. Asia Pacific Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%)	43
Figure 22. Asia Pacific Influenza Treatment Market: Influenza A, 2019-2030, $ mn	44
Figure 23. Asia Pacific Influenza Treatment Market: Influenza B, 2019-2030, $ mn	45
Figure 24. Asia Pacific Influenza Treatment Market: Influenza C, 2019-2030, $ mn	46
Figure 25. Breakdown of Asia Pacific Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue	47
Figure 26. Asia Pacific Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%)	48
Figure 27. Asia Pacific Influenza Treatment Market: Oral Administration, 2019-2030, $ mn	49
Figure 28. Asia Pacific Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn	50
Figure 29. Breakdown of Asia Pacific Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue	51
Figure 30. Asia Pacific Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%)	52
Figure 31. Asia Pacific Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn	53
Figure 32. Asia Pacific Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn	54
Figure 33. Asia Pacific Influenza Treatment Market: Clinics, 2019-2030, $ mn	55
Figure 34. Asia Pacific Influenza Treatment Market: Online Stores, 2019-2030, $ mn	56
Figure 35. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue	58
Figure 36. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%)	59
Figure 37.  Influenza Treatment Market in Japan, 2019-2030, $ mn	61
Figure 38.  Influenza Treatment Market in China, 2019-2030, $ mn	63
Figure 39.  Influenza Treatment Market in Australia, 2019-2030, $ mn	65
Figure 40.  Influenza Treatment Market in India, 2019-2030, $ mn	67
Figure 41.  Influenza Treatment Market in South Korea, 2019-2030, $ mn	69
Figure 42.  Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn	71
Figure 43. Growth Stage of Asia Pacific Influenza Treatment Industry over the Forecast Period	73

Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca Plc	
BioCryst Pharmaceuticals Inc.	
Biondvax	
Daiichi Sankyo Company	
F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)	
GlaxoSmithKline Plc	
Mylan N.V	
Natco Pharma Limited	
Novartis AG	
Sanofi	
Seqirus	
Teva Pharmaceutical Industries Limited